Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Novel therapies in genitourinary cancer: an update | BioMed Central Journal of Hematology Oncology Review Novel therapies in genitourinary cancer an update David Chu and Shenhong Wu Address Department of Medicine Stony Brook University Medical Center Stony Brook New York USA Email David Chu - dchu@ Shenhong Wu - Corresponding author Open Access Published II August 2008 Received 15 July 2008 Journal of Hematology Oncology 2008 1 11 doi 1756-8722-1-11 Accepted 11 August 2008 This article is available from http content 1 1 11 2008 Chu and Wu licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract In recent years new treatment for renal cell carcinoma RCC has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as targeted therapy now available both medical oncologists and urologists are progressively more hopeful for better outcomes. The new remedies may provide patients with improved survival and at the same time less toxicity when compared to traditional cytotoxic agents. This article will center on current and emerging treatment strategies for advanced RCC and other GU malignancies with updates from 2008 annual ASCO meeting. Renal cell cancer For many years the treatment of advanced RCC was limited to the immunotherapy with interleukin-2 IL-2 and interferon-a IFN-a . The advent of targeted agents beginning in late 2005 filled a prolonged void of relatively fruitless therapies. The approval of the tyrosine kinase inhibitor sorafenib in December 2005 both opened the door for the entrance of numerous other agents that became readily available and also gave new optimism to patients afflicted with RCC. The incidence of RCC has nearly doubled in the past two decades it .
